相互作用
Aprepitant + Encorafenib
重症度: 重大
Aprepitant and Encorafenib: major interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Aprepitant can increase encorafenib concentrations through CYP3A4 inhibition. Higher exposure raises the risk of encorafenib toxicity including QT prolongation, dermatologic effects and hepatotoxicity.
この相互作用をわかりやすく説明すると
Aprepitant and Encorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Aprepitant belongs to Gastrointestinal Tract; Encorafenib belongs to Oncology.
なぜ起こるのか
Aprepitant inhibits CYP3A4, reducing the metabolism of encorafenib.
対処法
Prefer an antiemetic without CYP3A4 inhibition. If unavoidable, reduce encorafenib to half the dose and monitor QTc, then resume the prior dose after the inhibitor is stopped for 3 to 5 half-lives.
薬剤師に尋ねること
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、AprepitantとEncorafenibの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を14日間無料でお試し。カード登録不要。
Aprepitantのその他の相互作用
Encorafenibのその他の相互作用
よくある質問
Can I take Aprepitant with Encorafenib?
MediHelp rates the interaction as major. Aprepitant and Encorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Aprepitant can increase encorafenib concentrations through CYP3A4 inhibition. Higher exposure raises the risk of encorafenib toxicity including QT prolongation, dermatologic effects and hepatotoxicity.
How serious is the interaction between Aprepitant and Encorafenib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Prefer an antiemetic without CYP3A4 inhibition. If unavoidable, reduce encorafenib to half the dose and monitor QTc, then resume the prior dose after the inhibitor is stopped for 3 to 5 half-lives.
What other medicines interact with Aprepitant?
MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
